Home » The best stock in the S&P 500 in 2021 worries investors after + 360% YTD

The best stock in the S&P 500 in 2021 worries investors after + 360% YTD

by admin
  1. Home ››
  2. News >>
  3. World News ››


FACEBOOK
TWITTER
LINKEDIN

Spotlight on Moderna and BioNTech after the crashes of the two titles in the last 48 hours. In the pre-market, both show signs of recovery (+ 1.8% Moderna and + 4% BioNTech) after the violent sell-off of the last two sessions dictated by the fear that the two vaccine pioneers are traveling at too high valuations after the rally in three figures since the beginning of the year (both on Monday reached + 360% YTD).

Moderna shares fell by around 16% yesterday. Moderna has had an incredible run since the start of the year, making it by far the best stock in the S&P 500. After the release of the quarterly data, some analysts (Oppenheimer and Piper Sandler) cut their ratings on the stock. Additionally, Bank of America analyst Geoff Meachem wrote on Tuesday that Moderna’s valuation remains “unreasonable” and to justify the current market capitalization, an investor would assume that the company will sell up to 1.5 billion servings of its. vaccine against Covid-19 every year.

The Covid-19 vaccine news, however, has been positive for Moderna in recent days. In fact, pressures are mounting to get the population to get vaccinated and doctors at the Mayo Clinic published a preview of a study that found that, in a real-world study conducted in Minnesota, the effectiveness of the Moderna vaccine is superior to Pfizer when the Delta variant is dominant.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy